Tests heat therapy with radiotherapy for non-melanoma skin cancer
Tests combining heat treatment with radiotherapy in people with non-melanoma skin cancer.
Plain-language title generated from the registry record
Registry title: Skin Cancer and Hyperthermia and Radiotherapy
Key facts
- Where
- Aarau, Bern, Lucerne, and Winterthur, SwitzerlandSee the 4 sites
Where in Switzerland
- Kantonsspital AarauAarau, SwitzerlandTaking people
- LindenhofgruppeBern, SwitzerlandTaking people
- Luzerner KantonsspitalLucerne, SwitzerlandTaking people
- Kantonsspital WinterthurWinterthur, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Kantonsspital Winterthur KSW
- Trial code
- NCT06384053
- Record updated
- 15 June 2025
- Original description
The SAHARA trial assesses wether combining ultrahypofractionated accelerated radiotherapy (RT) with hyperthermia is as effective as standard hypofractionated high-dose radiation in treating non-melanoma skin cancer (NMSC).Read full original descriptionShow less
Skin Cancer and Hyperthermia and Radiotherapy - SAHARA a Two-arm, Open-label, Randomized Controlled Phase II Trial
The SAHARA trial assesses wether combining ultrahypofractionated accelerated radiotherapy (RT) with hyperthermia is as effective as standard hypofractionated high-dose radiation in treating non-melanoma skin cancer (NMSC).
Inclusion: Personally signed and dated written informed consent; Histologically confirmed invasive non-melanoma skin cancer (NMSC), including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) of any differentiation; ≥ T2 (TNM Classification 8th Edition); Tumor thickness up to 2cm (Maximum Depth invasion and/or exophytic growth, measured on pathology report or imaging); Local recurrence allowed, if primary treatment longer ago than 6 months (after primary treatment other than radiotherapy (RT)); Age ≥ 65 years; Eastern Cooperative Oncology Group (ECOG) performance status 0-2, with a life expectancy of more than 6 months; Presentation at the Swiss Hyperthermia Network (SHN) tumor conference mandatory.
Exclusion: Tumors after resection (R1 or R2 as well as adjuvant indication); Several lesions exceeding the capacity of one treatment/radiation field (multiple lesions within one treatment field are acceptable); Previous (one month) or concurrent Chemo- or Immunotherapy; Lesions inside or in proximity (within 3cm) previously irradiated area; wIRA-specific exclusion criteria; Tattoos in irradiated area; Increased photosensitivity (either due to simultaneous treatment with photosensitivity-enhancing medications or conditions such as porphyria); Patients with connective tissue disorders (e.g. Sclerodermia, Lupus erythematodes); Other histology than BCC or SCC; T1 tumor and/or N+ (according to TNM classification 8th edition); Tumor invasion into critical areas; Medical immunosuppression.